StockData
BioAge Labs, Inc. logo

BioAge Labs, Inc. (BIOA) stock

BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$4.77−0.33 (-6.47%)

Close on Nov 18, 2026Market cap $218.93MP/E –Yield –

BioAge Labs free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

BioAge Labs's free cash flow for the twelve months ending Jun 30, 2026 was -$88.09M. For fiscal 2025 it was -$82.35M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$82.35M–
FY2024Dec 31, 2024-$51.89M–
FY2023Dec 31, 2023-$37.53M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.59M–
Q1 FY2026Mar 31, 2026-$24.07M–
Q4 FY2025Dec 31, 2025-$28.36M–
Q3 FY2025Sep 30, 2025-$16.07M–
Q2 FY2025Jun 30, 2025-$20.13M–
Q1 FY2025Mar 31, 2025-$17.79M–
Q4 FY2024Dec 31, 2024-$5.16M–
Q3 FY2024Sep 30, 2024-$15.24M–
Q2 FY2024Jun 30, 2024-$15.82M–
Q1 FY2024Mar 31, 2024-$15.67M–
Q4 FY2023Dec 31, 2023-$8.50M–

More BioAge Labs figures

See a number that looks wrong?